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Abstract
Background: Collaborative efforts of physicians and basic scientists are often necessary in the
investigation of complex disorders. Difficulties can arise, however, when large amounts of
information need to reviewed. Advanced information retrieval can be beneficial in combining and
reviewing data obtained from the various scientific fields. In this paper, a team of investigators with
varying backgrounds has applied advanced information retrieval methods, in the form of text mining
and entity relationship tools, to review the current literature, with the intention to generate new
insights into the molecular mechanisms underlying a complex disorder. As an example of such a
disorder the Complex Regional Pain Syndrome (CRPS) was chosen. CRPS is a painful and
debilitating syndrome with a complex etiology that is still unraveled for a considerable part,
resulting in suboptimal diagnosis and treatment.
Results: A text mining based approach combined with a simple network analysis identified Nuclear
Factor kappa B (NFκB) as a possible central mediator in both the initiation and progression of
CRPS.
Conclusion: The result shows the added value of a multidisciplinary approach combined with
information retrieval in hypothesis discovery in biomedical research. The new hypothesis, which
was derived in silico, provides a framework for further mechanistic studies into the underlying
molecular mechanisms of CRPS and requires evaluation in clinical and epidemiological studies.
Background
Early in the history of western medicine, the physician
and the basic scientist were one and the same person.
However, over the past century, clinical research devel-
oped as a separated branch from the basic sciences such as
biology, molecular biology, biochemistry, and physiol-
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tion and analysis of clinical data concerning symptoms of
the disorders and responses to treatments. Based on these
observations new theories about etiology and pathogene-
sis can be developed. However, detailed information
regarding the molecular mechanisms underlying a certain
disease process often remains elusive. One avenue into
possible mechanisms of complex disorders is through the
use of bioinformatics. Bioinformatics applies informatics
techniques to organize bio-molecular data on a large scale
[1].
The combination of bioinformatics and biomedical
approaches is expected to result in significant advantages
in both understanding mechanisms of disorders and indi-
vidual susceptibility, which in turn will open many possi-
bilities in individualized medical health care [2].
INFOBIOMED is a Network of Excellence funded by the
European Union that aims at enforcing European bio-
medical informatics as an integrative discipline [3,4]. One
of the main objectives of INFOBIOMED is to enable pilot
applications in several medical fields that demonstrate the
benefits of a synergetic approach in biomedical informat-
ics. An example of such a multidisciplinary project is the
use of bioinformatics tools in the investigation of the rela-
tionship between clinical and molecular data. Of course,
the current literature contains information from these dif-
ferent domains. However, the amount of information has
become so large that it is very difficult for a single individ-
ual to draw conclusions across the various disciplines. Lit-
erature based discovery support tools have been
developed to bridge these interdisciplinary gaps, and
novel scientific hypotheses have been generated and
tested [5,6]. This approach, wherein the clinician and the
basic scientist collaborate, should be beneficial in the
investigation of complex disorders, where clinical
research alone is not sufficient to unravel the entire disor-
der process.
Case studies can be useful in exploring new ways to
advance multidisciplinary biomedical research. The Com-
plex Regional Pain Syndrome (CRPS) is an example of a
complex disorder from which the etiology and pathogen-
esis remain unelucidated for a considerable part, despite
intensive research in the medical field. For this reason
CRPS was chosen as a case study on how text mining tech-
niques could be used in multidisciplinary biomedical
focused research. The results should not be regarded as
answers to the long unsolved questions regarding CRPS,
but rather as hypothetically new insights in the molecular
mechanisms underlying the disorder. The main purpose
of this exercise was to assess the benefit of a new approach
on hypothesis discovery, based on the use of text mining
tools by a multidisciplinary team of researchers.
A brief introduction will be provided on the disorder
CRPS in the next section, including a short description of
the current theories about its pathogenesis.
The Complex Regional Pain Syndrome
CRPS is a painful syndrome affecting one or more extrem-
ities of the body, marked by a wide variety of symptoms.
The most prominent feature is pain, including spontane-
ous pain, allodynia, hyperpathia, and hyperalgesia. Addi-
tionally, the affected extremity can display changes in
color and/or temperature (vasomotor disturbances),
edema, alterations in transpiration, hair and nail growth
(sudomotor disturbances), and muscular atrophy and/or
dysfunction (motortrophic disturbances) [7,8]. It is usu-
ally described after a specific initiating event, in most cases
a trauma or an operation, but sporadically it is observed
after a stroke, myocardial infarction, infection or even
without an obvious inciting event in a rarity of the cases
[9]. The course of the disorder varies from patient to
patient, but often ends in diminished function of the
affected limb which impacts the quality of life of the
patient. In rare cases, the disorder progresses to the point
where amputation is necessary.
The pathogenesis of CRPS evolves from disturbances in
both the peripheral nervous system (PNS) and the central
nervous system (CNS) (figure 1). Regarding the initial
phase of the disorder, recently the interest has increased
towards the role of inflammatory responses. Inflamma-
tory signs such as swelling, redness, warmth and pain are
common features in the early stage of CRPS. Classic
inflammation is marked by the presence of proinflamma-
tory cytokines and in CRPS a local increase of the
cytokines TNFα, IL-6 and tryptase (a product of mast cell
degranulation) was observed in blister fluid derived from
the affected extremity [10,11]. IL-1 and IL-6 were also
found to be increased in spinal fluid [12]. Additional to
classic inflammation, a process called neurogenic inflam-
mation has been demonstrated in CRPS [13-17]. Neuro-
genic inflammation resembles classic inflammation, but
it is initiated by neuropeptides instead of lymphocytes
and cytokines [18]. Those neuropeptides include Sub-
stance P (SP), Calcitonin Gene Related Protein (CGRP),
neuropeptide Y (NPY), Bradykinin (BK) and Vasoactive
Intestinal Protein (VIP). Important modulators of neuro-
genic inflammation are Neutral Endopeptidase (NEP)
and Angiotensin Converting Enzyme (ACE) [19].
Endothelial dysfunction, hypoxic changes, and free radi-
cal damage have also been suggested as important proc-
esses in the pathogenesis of CRPS [20-24]. Ischemia,
together with inflammation, can result in the formation
of free radicals, lactate acidosis and altered nitric oxide
(NO) synthesis. The NO metabolism in its turn has an
effect on the microcirculation and thus can influencePage 2 of 16
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tion might underlie a cold extremity that is observed in
some cases of CRPS.
In time, the peripheral alterations give rise to disturbances
at the level of the CNS, and the clinical picture of CRPS
evolves more towards that of a neuropathic pain syn-
drome. The mechanisms behind the development of neu-
ropathic pain have been investigated extensively in
animal models [26,27]. The pathogenesis of neuropathic
pain is marked by a phenomenon called neural plasticity,
which is described by Woolf and Salter as the capacity of
central and peripheral neurons to change their function,
chemical profile, and their structure in reaction to activa-
tion of peripheral afferent nerve endings [28]. This con-
ducts towards a state of hyperexcitability of the peripheral
C- and A-fiber transducers, and of the neurons in the dor-
sal root ganglia (DRG) of the CNS, referred to as periph-
eral and central sensitization respectively. Sensitization
results in a painful response to a normally not painful
stimulus, leading to features as allodynia and hyperalge-
sia. A prominent factor in the evolvement of sensitization
is the interaction between glutamate and the N-methyl-D-
aspartate (NMDA) receptor, from which functional status
Mg2+ is a modulator [28]. Following central sensitization,
alterations at the supraspinal level might evolve, resulting
The pathogenic mechanisms in CRPSFigure 1
The pathogenic mechanisms in CRPS. The four pathogenic mechanisms in CRPS and their interactions. SP = substance P, 
CGRPS = Calcitonin Gene Related Protein, VIP = Vasoactive Intestinal Protein, NPY = Neuropeptide Y, NPY-Y1-R = Neu-
ropeptide Y-Y1 receptor, NEP = Neutral Endopeptidase, ACE = Angiotensin Converting Enzyme, SMP = Sympathetically Main-
tained Pain, NO = nitric oxide, iNOS = inducible nitric oxidase, ONOO = peroxynitrite, NMDA-R = N-methyl-D-Aspartate 
receptor, NK1-R = Nuerokinin-1 receptor, CNS = central nerve system, PNS = peripheral nerve system.
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pays an additional contribution to the sensational distur-
bances in chronic CRPS [29].
Dysregulation of the sympathetic nerve system was classi-
cally supposed a main feature of CRPS. This was based on
the observation that pain relief could be obtained by per-
forming a sympathectomy, although only in a subset of
CRPS patients. Vasomotor disturbances (warm or cold
limb) [30] and sympathetically maintained pain (SMP)
[31-34] are features that have been ascribed to sympa-
thetic dysregulation. The painful responses may result
from the expression of α-adrenoreceptors on sensory fib-
ers [34]. Due to sympathetic sprouting new communica-
tion pathways are formed between sympathetic terminals
and sensory neurons [35]. Additionally, the α-adrenore-
ceptors might have developed a hypersensitivity for nor-
mal stimulation by cathecholamines [30].
The authors have decided in this paper to focus mainly on
the peripheral processes in the initial phase of CRPS. The
first reason for this is that it is very feasible that the neuro-
pathic pain component of CRPS does not form the initial
pathogenesis of the disorder, but that it is preceded and
sustained by the presence of the peripheral inflammatory
and hypoxic reactions in the affected extremity [35], The
second reason is that, until now biomolecular research on
CRPS in humans and animals concerned mostly the
peripheral inflammatory aspect of the disorder. Sensitiza-
tion and neuronal plasticity have been studied broadly in
models for neuropathic pain in general. However, they
have never been demonstrated in models for CRPS in par-
ticular, although is it highly reasonable to assume that
they occur in CRPS in a similar manner.
Methods
The INFOBIOMED Network of Excellence is organized
into various work packages with different aims [3]. The
aim of the so called "pilot applications" is to analyse the
impact of biomedical informatics in specific fields (Phar-
mainformatics, Genomics and Microbiology, Genomics
and Chronic Inflammation, and Genomics and Cancer).
The team of researchers behind the study outlined in this
paper was part of the pilot application Pharmainformat-
ics, which aims at assessing the mutual impact of BMI and
pharmaceutical research. Research in this area focuses on
establishing the information continuum pathology –
pathway – target – ligand.
The pathogenesis of CRPS was one of the subjects that
were chosen for a case study. The purpose was to investi-
gate how to gain further insight into pathogenesis behind
a complex disease and to identify possible pathways, tar-
gets and ligands for improving pharmacological therapy,
using a multidisciplinary approach. The team of research-
ers had varying backgrounds mirroring the biomedical
informatics research area (one physician with domain
expertise on CRPS that was asked to participate in the
work package only for this specific case study; one bioin-
formatician; one specialist in text mining). No formal
leader was chosen for the group. All researches provided
input based on their background and a plan of action took
form by mutual agreement. The physician provided bio-
logical and medical concepts that are possibly linked to
CRPS, the bioinformatician provided the appropriate soft-
ware tool to be used in the study, and the text mining
expert provided knowledge on how to best perform the
extensive literature analysis. The analysis took place in
September 2004, at the premises of AstraZeneca in Mol-
ndal, Sweden.
The selection of the CRPS related concepts was based on
current (but not always objectified) opinions about the
pathogenesis and treatment of CRPS and on different
pathogenic mechanisms described in a selection of arti-
cles concerning the pathogenesis of CRPS [33,36-39]. The
focus was on chemical and biochemical identities and
mainly, but not completely, on the peripheral compo-
nents of the disorder. The collection of concepts and their
synonyms can be found in Table 1.
The text mining/entity relationship tool PathwayAssist™
(Version 2.5) was used to visualize the connections
between the CRPS concepts in a network and to search for
new concepts taking part within these relations. Pathwa-
yAssist is a software application developed for navigation
and analysis of biological pathways, gene regulation net-
works and protein interaction maps. It has been used
before in studies to identify genes that are involved in
autism [40] and in regulation of human primordial folli-
cle development [41]. The application has been described
in more detail by Nikitin and colleagues [42]. PathwayAs-
sist finds connections between concepts, henceforth
referred to as 'nodes', by searching through a database of
interactions derived from literature, using the natural lan-
guage processing (NLP) based software MedScan. MedS-
can performs a grammatical and semantic analysis of the
complete MEDLINE® database of life sciences and bio-
medical bibliographic information. The MedScan soft-
ware has been described by Novichkova et al. [43] and
more recently by Daraselia et al. [44]. A brief overview of
the technology is presented below.
When parsing a MEDLINE document, a semantic inter-
preter of the NLP component transforms the syntactic
structure into a semantic structure. The syntactic structure
and main constituents (surrounded by square brackets) of
a sentence can be exemplified using the general sentence
Protein X inhibits protein Y, which has the syntactic struc-
ture of [Protein X[N]] [NP] [inhibits[V] Protein Y [N]] [VP]] [S]. ThePage 4 of 16
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constituent (NP designates noun phrase, N designates
noun, V designates verb, VP designates verbal phrase, S
designates sentence). The syntactic structure will be trans-
formed to a semantic frame of inhibition that has an
'agent' protein X and a 'patient' protein Y. The output of
the semantic parse is the input for an ontological analysis
that was developed by Daraselia et al. [44]. In this an
'entity' is represented either as a protein, a cellular object,
a cellular process, or a small molecule and 'controls'
describe functional relationships between these entities.
Relations between entities are stored in a relational data-
base. These relations can be displayed and explored
through a graphical interface.
The list of concepts provided by the physician was
regarded as current knowledge about CRPS (table 1) and
was used as input for PathwayAssist. PathwayAssist views
these concepts as nodes. The option "find only direct
interactions between selected nodes" was used to search
the underlying interaction database for direct connections
between the CRPS concepts. Based on these connections,
the system builds a network. This procedure would only
detect direct relationships between two nodes; mecha-
nisms that require a new intermediate node (a node not
present in the original list of nodes that was provided as
input) would not be detected. Such intermediate nodes,
however, might represent knowledge that the scientists
entering the concepts were not aware of at the time of
input (such as factors acting as enhancers for a critical step
in a pathway, or co-factors needed for a transcription fac-
tor to bind to DNA). Therefore, an option was used that
incorporates a new node in the network if that node is the
intermediate node that allows the creation of a triplet con-
necting two input nodes. When a new node is added to
the network, all links to and from that node to all other
nodes in the network are displayed.
Results
The resulting network based on the imported CRPS con-
cepts is shown in Figure 2. In addition to the original con-
cepts that were provided as input nodes, six new nodes
have been added by the algorithm (nodes that were not in
the original list of concepts known to be associated with
CRPS). Of these six new nodes, the node NFκB was the
one connecting to most of the original CRPS concepts and
was pivotal in the final network. NFκB appeared as new
node because it was part of a triple connection between
mannitol and TNFα with the actual sentence being 'High
glucose or mannitol also enhanced TNFalpha-stimulated
NF-kappaB activity': TNFα stimulates NFκB, and manni-
tol acts as an enhancer of this process. The sentence
describing this particular relationship between mannitol,
TNFα, and NFκB had been parsed from the article by Hat-
tori et al [45].
The transcription factor NFκB is known as a mediator in
many different physiological processes [46,47]. It is also
related to 7% of all the nodes that exist in PathwayAssist,
which mirrors its versatility. However, even though NFκB
has a very high connectivity in PathwayAssist and is
involved in many physiological processes, the calculated
p-value using a one-tailed Chi-square test with Yates's cor-
rection was highly statistically significant (p-value less
than 0.0001). This demonstrates the significance of NFκB
in the CRPS network in comparison to the whole Pathwa-
yAssist database of interactions.
To investigate the possibility that NFκB appeared in the
network simply because it is a highly connected node in
the database, the in PathwayAssist equally highly con-
nected node "protein tumor protein p53" was manually
included into the network and tested for its connectivity
with the CRPS concepts. The p-value was found to be
equally significant as for NFκB (p-value less than 0.0001).
Table 1: Concepts used when building the CRPS network in PathwayAssist (description in parenthesis).
Node Type Node Name
Complex Neuronal acetylcholine receptor[16, 98]
Functional Class NMDA receptor (N-methyl-D-aspartate receptor) [16, 98]
Protein CALCA (calcitonin/calcitonin-related polypeptide, alpha[46, 51]), IL1A (interleukin 1 alpha) [99], IL6 (interleukin 6) [13], 
NGFB (nerve growth factor, beta polypeptide), NGFG (nerve growth factor, gamma subunit) [79], NPY (neuropeptide 
Y[100]) [10], PTGS1 (prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)[101]) [10], 
TAC1 (tachykinin, precursor 1 (substance K, substance P, neurokinin 1, neurokinin 2, neuromedin L, neurokinin) [10], TACR1 
(tachykinin receptor 1), TNF (tumor necrosis factor) 24, BDKRB2 (bradykinin receptor B2[45, 56, 57]) [102], PTGS2 
(prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)) [20], NTRK1 (neurotrophic 
tyrosine kinase, receptor, type 1) 72, TRPV1 (transient receptor potential cation channel, subfamily V, member 1), Ngfa (nerve 
growth factor, alpha), BDK (Bradykinin), VIP (vasoactive intestinal peptide)
Small Molecule glutamate, DMSO (Dimethyl sulfoxide), PGE2 (Prostaglandin E2), magnesium, noradrenaline, capsaicin, glucocorticoid, 
mannitol, pentoxifylline, naproxen, bisphosphonate, verapamil, morphine, ketamine, amitriptyline, clonidine, carbamazepine, 
nortriptyline, lidocaine, GABA (gamma-aminobutyric acid), ketanserin, infliximab, gabapentin, amantadine, lioresal, 
benzodiazepine, Baclofen, N-acetyl-cysteinPage 5 of 16
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network is related to on the algorithm that was chosen to
find new nodes. In order for a new node to be incorpo-
rated into the network by PathwayAssist it has to be part
of a triplet that connects two input nodes. This was the
case for NFκB but not for TP53. There are also other algo-
rithms available in PathwayAssist for incorporating new
nodes in a network. These include an algorithm to find
the shortest paths between the nodes in the network, an
algorithm to find common targets, an algorithm to find
common regulators, and also an option to expand the net-
work by finding all nodes in the database that are con-
nected to the nodes in the network. The shortest paths
algorithm yielded 20 new nodes, the common target algo-
rithm 46 new nodes and the common regulators algo-
rithm yielded 38 new nodes. The option of finding all
nodes connected to the nodes in the CRPS network (the
expanded network algorithm) yielded 3872 nodes and it
was considered to be practically infeasible to analyze all
these nodes separately for their connectivity in the CRPS
network. Neither NFκB nor TP53 were found by using any
of the other algorithms except for the expand network
algorithm. Thus, it might be possible that NFκB emerged
in the CRPS network simply because it is a highly con-
nected node in the whole PathwayAssist database. How-
ever, NFκB was still connected to more nodes in the CRPS
network than the reference node TP53. Therefore it was
still regarded as a candidate for a key role in the pathogen-
esis of CRPS
As far as the authors of this paper know, NFκB has never
before been mentioned together with CRPS. For this rea-
Resulting network of CRPS concepts from PathwayAssistFig re 2
Resulting network of CRPS concepts from PathwayAssist. The PathwayAssist network shows that NFκB is connected 
with many concepts that are related to CRPS. Red circles denote proteins, red hexagons denote protein complexes, green cir-
cles denote small molecules, orange circles denote enzymes, and orange hexagons denote protein functional classes. Concepts 
for which PathwayAssist could not find a link to any other of the concepts in the network are shown in the upper left.Page 6 of 16
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explored further by manual research of literature, using
advanced PubMed queries concerning the relation
between NFκB and the CRPS concepts. Based on the
results of this literature research, and on discussions about
this topic within the Pharmainformatics group of the
INFOBIOMED network of excellence, theories for the
involvement of NFκB in the described pathogenic mecha-
nisms in CRPS were developed. A summary of these theo-
ries is described table 2 and further explained below.
Role of NFκB in CRPS related mechanisms
1) NFκB involvement in neurogenic and classic inflammation
NFκB has been demonstrated to be an essential transcrip-
tion factor in the mediation of the effects of neuropep-
tides that are also involved in CRPS: 1) SP induced
expression of IL-6 and TNFα (cytokines that are locally
increased in CRPS) is regulated by NFκB [48,49]; 2) Gluta-
mate, released in the dorsal horn together with SP induces
neuronal apoptosis through NFκB induction [50]; 3)
Expression of CGRP (an important neuropeptide in
CRPS) is induced by an NFκB mediated pathway, initiated
by IL-1β stimulation [12]; 4) Bradykinin activates NFκB
and cyclooxygenase-2 via more than one pathway [46,51];
5) VIP inhibits NFκB mediated chemokine production by
macrophages [52]. It also prevents NFκB from binding to
the promotor site for nitric oxide synthethase iNOS,
thereby affecting the microcirculation in CRPS [53]; 6) For
the NPY receptor, potential NFκB binding sites have been
found in the promoter regions, suggesting a role for NFκB
in the expressional regulation of this receptor [54]; 7) The
important inflammatory modulator ACE reduces NFκB
activity [55]. The overall effect appears to be that NFκB
activity is upregulated by the neuropeptides involved in
CRPS, resulting in a pro-inflammatory response mediated
through NFκB.
2) NFκB involvement in hypoxic changes
NFκB activity is inhibited by NO [45,56,57]. However,
peroxynitrite (ONOO), which is formed from NO after
reaction with radical oxygen intermittents, sustains NFκB
activity [45]. NFκB also is involved in the expression of
inducible nitric oxide synthethase (iNOS) induced by pro-
inflammatory cytokines TNFα and IL1-β, which are
locally elevated in CRPS [10,58]. Additionally, NFκB
activity is involved in and affected by free radical forma-
tion [50,59,60] and acidosis [22,61,62].
3) NFκB and neuropathic pain
Several animal models demonstrate the role of NFκB in
pain induction and pain maintenance in the CNS. For
example, NFκB is involved in the upregulation of some
types of NMDA receptors which are important mediators
in the development of central sensitization [63]. Addi-
tionally, NFκB in the CNS mediates IL-1 induced COX-2
up-regulation and prodynorphin expression [64,65]. The
derived compound dynorphin is an endogenous opiate
that causes hyperalgesia and allodynia in mice. In line
with this, intrathecal (in the central spinal fluid) or neu-
ronal injected NFκB inhibitors attenuate proinflamma-
tory cytokine mediated pain in rats [66,67].
4) NFκB involvement in sympathetic dysregulation
Pro-inflammatory responses induced by the catecho-
lamines derived from the sympathetic nervous system,
which might be dysregulated in CRPS, are mediated by
NFκB [68-70]. Additionally, NFκB up-regulates directly
the expression of the β-adrenoreceptor on immune cells
[71]. Moreover, the expression of the α-receptor might be
Table 2: Key concepts and their relations to CRPS and NFκB
Key concept Relation to CRPS Relation to NFκB
Substance P Locally elevated upon electrical C-fiber stimulation [16, 
98]
Induces NFκB mediated release of IL-6 and TNFα [103]
Calcitonin Gene-related Protein Systemically and locally elevated [13, 16, 98] Suppresses NFκB activity in thymic cells [104]
Bradykinin Systemically elevated [13] Activates NFκB [46, 51]
Vasoactive Intestinal Protein Systemically elevated [13] Locally decreased [99] Inhibits NFκB mediated chemokine production by macrophages [52]. 
Prevents NFκB binding to promoter site for NO [52]
Neuropeptide Y Systemically elevated [13] NPY-Y1-R expression is regulated by NFκB [54]
Neutral Endopeptidase Speculated to be decreased [19] No relation with NFκB described
Angiotensin Converting Enzyme Speculated to be decreased [19] Polymorphism in CRPS 
patients [79]
Reduces NFκB activity [55]
TNFα Locally increased [10] Induced by NFκB [48], Activates NFκB [100]
IL-1β Locally increased [10] Stimulates NFκB mediated apoptosis in sympathetic neurons [101]
IL-6 Locally increased [10] Induced by NFκB [49]
Tryptase Locally increased [10] Induced by NFκB [103]
Free radicals Signs of free radical damage [24] Second messenger in NFκB activity [50, 59]
Nitric oxide Elevated after monocyte stimulation [102] NO reduces NFκB activity, but ONOO induces NFκB [45, 56, 57]
Protons (acidosis) Lactate increased in skin [20] Influences NFκB activity [22, 61, 62]
α-receptor Up-regulated in analgesic skin ([72] Pro-inflammatory responses mediated through NFκB [68-70]
Sympathetic neuron Speculated to be damaged in CRPS [105] NFκB mediates Il-1βinduced apoptosis [101]
NMDA receptor Role in development of central sensitization [28]. NFκB is involved in the up-regulation of some types of NMDA receptors 
[63].Page 7 of 16
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mediated apoptosis of sympathetic neurons, leading to
up-regulation and/or hypersensitivity of the peripheral α-
receptors expressed on blood vessels, immune cells, and
nociceptive primary afferents [72].
Discussion
This paper describes how a multidisciplinary team of
investigators applied advanced information retrieval
methods, in the form of a text mining/entity relationship
tool, with the purpose of discovering new hypotheses con-
cerning the pathogenesis of a complex disorder, exempli-
fied here by CRPS. The exercise should be regarded as a
"journey" to discover what benefit could emerge from this
kind of collaboration between bioinformatics experts and
clinical experts. The purpose was neither to assess the spe-
cificity of the used methodology, nor to discover complete
underlying biochemical pathways.
The text mining/entity relationship tool PathwayAssist
provided a new concept, named NFκB, which is related to
a majority of the concepts described to be involved in
CRPS. After manual literature search, NFκB appeared to be
a link between the various, previously described patho-
genic mechanisms and appeared to serve as a mediating
component in their connections.
Validity of the method
The MedScan system has been manually validated by the
developers through random extraction and analysis of
direct physical protein-protein interactions from
MEDLINE [44]. From the interactions extracted by MedS-
can, 91% was correct (precision). Most errors were attrib-
uted to the extracted functional interference between
proteins rather than physical interaction. Coverage
(recall), however, was low: 21%. This is primarily due to
the low coverage rate of the NLP component (34%). The
concept network on CRPS (figure 2) was validated manu-
ally by the authors of this paper by checking all relations
leading to or from NFκB. Out of 38 relations, 34 were cor-
rect and 4 incorrect.
Naturally, it would be helpful if some sort of independent
relevance score could be provided for new hypotheses
generated by the method used in this report. In this view,
a p-value was calculated for the new node NFκB in the net-
work using a one-tailed Chi-square test with Yates's cor-
rection, comparing its node connectivity in the
PathwayAssist database to its node connectivity in the
CRPS concepts network. In addition, the protein TP53
was chosen as a reference case because of the equally high
connectivity in the PathwayAssist database compared to
NFκB. Unfortunately, TP53 was found to be equally sig-
nificant in the CRPS network as NFκB. However, NFκB
was connected to more concepts in the original CRPS net-
work than TP53.
An automatic network analysis approach where a variety
of nodes (for example all highly connected proteins in the
PathwayAssist database, all nodes generated by the
expanded network algorithm, or simply all nodes in the
PathwayAssist database) would be tested for positive asso-
ciation to a subnetwork of predefined disease-specific
nodes would be valuable for both hypotheses generation
and testing. Unfortunately, there is no such algorithm
available in the PathwayAssist version used by the authors
of this paper. Furthermore, the necessary data (specific
connectivity information for each node in the database,
i.e. which other nodes it is connected to) required for car-
rying out these types of tests outside the framework of the
tool are not provided by PathwayAssist. The assessment of
the connectivity to the CRPS network for NFκB and TP53
was performed manually inspection, an activity that is
very time consuming and not defendable for a larger
number of nodes. Despite the limitations regarding the
assessment of the specificity of the results, a new node
found by one of the network gap analysis algorithms pro-
vided by PathwayAssist, which was significantly related to
the CRPS network, was considered important enough for
further investigation.
One should bear in mind that results from text mining
exercises as described in this paper are far from the solu-
tion to the medical problem or the complete answer to
outstanding questions. The current tools in the biomedi-
cal domain are not capable of delivering clear and already
assessed hypotheses. However, in this case, the results of a
simple knowledge gap analysis provided a new idea that,
after further manual exploration in literature, appeared
very plausible and worthwhile investigating in biological
experiments and epidemiological studies.
The generalizability of this method of hypothesis discov-
ery needs to be assessed by repeating the exercise for other
complex medical conditions. However, it would be an
exhaustive and extremely time consuming task to repeat
the exercise for a large group of complex disorders. This is
a well-known problem in the evaluation of text mining
tools in general [73].
Testing the new hypothesis
New biological data are needed to verify the in silico
derived hypothesis concerning the involvement of NFκB
in the pathogenesis of CRPS. These data could be gener-
ated through animal models, clinical studies, and epide-
miological studies. A rat model for CRPS has been
developed by Coderre and colleagues [74]. They named it
the chronic post ischemia pain (CPIP) model, since CRPS
like symptoms are provoked by ischemia and reperfusionPage 8 of 16
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quet. This model may prove useful to investigate the role
of NFκB in the early development of CRPS, for example by
measuring the transcription of NFκB in the affected tissue.
Additionally, in this model the effect of administration of
NFκB inhibitors could be studied. In the past, NFκB
knockout and transgenic animal models have been exten-
sively used to study the NFκB pathway [75]. An increased
inflammatory response coupled with an increased suscep-
tibility to opportunistic infections has been recorded
[76,77], and a decrease of the electroacupuncture-induced
analgesic effects has also been shown [78]. A failure to
induce CRPS like symptoms in NFκB knock mice would
support the hypothesis of a NFκB as a crucial factor in
CRPS.
Clinical and epidemiological studies to test the hypothe-
sis could involve the investigation of determinants of
altered NFκB activity and the comparison in this view
between CRPS cases and healthy controls. For example it
could be tested whether other NFκB related disorders
(asthma, autoimmune disorders or atherosclerosis) co-
occur with CRPS. Viral infections are known to upregulate
NFκB activity. Thus the time relation between CRPS and
the occurrence of a viral infection may also be worthwhile
investigating. Finally, one could search for features from a
genetic origin. The increased prevalence of an ACE poly-
morphism in CRPS patients was found in a small study
[79]. Since ACE is also an inhibitor of NFκB activity, fur-
ther investigations regarding this polymorphism might be
of interest.
Certain drugs affect (perhaps unintentionally) the NFκB
pathway and could influence the development of CRPS
(see also section Targeting the NFκB pathway). Currently,
according to the recently developed Dutch evidence based
Guideline Complex Regional Pain Syndrome type 1 [80],
nine drugs have been proven beneficial in the prevention
The entire CRPS pathogenesis. Starting point: sympathetic dysregulationFigure 3
The entire CRPS pathogenesis. Starting point: sympathetic dysregulation. Mediated by NFκB, a trigger that induces 
sympathetic dysregulation can induce the entire pathogenesis of CRPS. SP = Substance P, CGRP = Calcitonin Gene-related 
Protein, VIP = Vasoactive Intestinal Protein, NPY = Neuropeptide Y, NPY-Y1-R = Neuropeptide Y-Y1 Receptor, NEP = Neu-
tral-Endopeptidase, ACE = Angiotensin Converting Enzyme, SMP = Sympathetically Maintained Pain, NO = Nitric Oxide, iNOS 
= inducible Nitric Oxidase, ONOO = peroxynitrite
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tine [82], DMSO crème [83], N-acetylcysteine [83], corti-
costeroids [84], bisfosfonates [85], calcium antagonists
[86], ketanserine [87], and vitamin C [88]. Interestingly,
126 small molecules are listed as NFκB inhibitors in Path-
wayAssist, and 5 of these overlap with the list of drugs
proven beneficial for preventing or treating CRPS (keta-
mine [89], DMSO crème [90], N-acetylcysteine [91], cor-
ticosteroids [92], and calcium antagonists [93]).
A Dutch cohort of CRPS patients was identified in the
Integrated Primary Care Database (IPCI), a database that
makes electronic patient records used in routine care
available to investigators [94]. This cohort has been used
before in research on CRPS [95] and will be used for fur-
ther testing of these hypotheses within the framework of
INFOBIOMED.
Clinical relevance
NFκB is a transcription factor that is known to be involved
in many processes, but its function is best described in
inflammation [46]. In the recent past NFκB has been dis-
covered as an important mediator in diseases due to
chronic and exaggerated inflammatory responses, includ-
ing sepsis, asthma, rheumatic disorders, inflammatory
bowel disease, and psoriasis. However, in the current
available literature NFκB has never before been men-
tioned in association with CRPS. Therefore, this relation is
The entire CRPS pathogenesis. Starting point: classic inflammationFigure 4
The entire CRPS pathogenesis. Starting point: classic inflammation. Mediated by NFκB, a trigger that induces classic 
inflammation can induce the entire pathogenesis of CRPS. SP = Substance P, CGRP = Calcitonin Gene-related Protein, VIP = 
Vasoactive Intestinal Protein, NPY = Neuropeptide Y, NPY-Y1-R = Neuropeptide Y-Y1 Receptor, NEP = Neutral-Endopepti-
dase, ACE = Angiotensin Converting Enzyme, SMP = Sympathetically Maintained Pain, NO = Nitric Oxide, iNOS = inducible 
Nitric Oxidase, ONOO = peroxynitrite
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exercise. Especially remarkable is that, in the generated
network, NFκB is not only linked with the inflammatory
concepts related in CRPS, but also to the non-inflamma-
tory concepts in CRPS, such as neuropeptides and cate-
cholamines.
Realizing the possible central role for the NFκB pathway
in the mechanisms underlying CRPS (or in the stress
response caused by CRPS), unanswered questions con-
cerning the disorder can be reviewed from a new point of
view. For instance, when placing NFκB in the centre of the
pathogenic process, the wide variety of precipitating
events could be explained by the observation that all path-
ogenic mechanisms in CRPS are related to each other. This
relation suggests that an event that specifically triggers one
of the four mechanisms induces the entire complex path-
ogenic process (figure 3, figure 4, figure 5, and figure 6).
For each mechanism separately the potential triggers are
limited, but for the four mechanisms together the possi-
bilities are numerous. With the addition of NFκB, the bio-
chemical picture underlying CRPS becomes one in which
several processes can initiate the disorder and in which
NFκB can play a key role in its propagation.
Assuming the central unifying role of NFκB in the patho-
genesis of CRPS, independent whether NFκB is the final
molecule in the pathway or not, new targets for drug ther-
The entire CRPS pathogenesis. Starting point: neurogenic inflammationFigure 5
The entire CRPS pathogenesis. Starting point: neurogenic inflammation. Mediated by NFκB, a trigger that induces 
neurogenic inflammation can induce the entire pathogenesis of CRPS. SP = Substance P, CGRP = Calcitonin Gene-related Pro-
tein, VIP = Vasoactive Intestinal Protein, NPY = Neuropeptide Y, NPY-Y1-R = Neuropeptide Y-Y1 Receptor, NEP = Neutral-
Endopeptidase, ACE = Angiotensin Converting Enzyme, SMP = Sympathetically Maintained Pain, NO = Nitric Oxide, iNOS = 
inducible Nitric Oxidase, ONOO = peroxynitrite
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at targeting separate mechanisms. However, targeting one
mechanism in CRPS is not enough, as made apparent by
the limited success rate for the majority of treatments.
Based on the new hypothesis, targeting the NFκB pathway
may provide a way to target all the underlying mecha-
nisms at once. Thereby, progression of the disorder may
be more effective, since it will be prevented at more than
one level. Independent from the inciting event or princi-
ple disturbed mechanism, NFκB pathway inhibitors
might remove the 'engine' that keeps the process running.
Targeting NFκB as a therapy in sepsis, inflammatory dis-
eases and neuronal diseases is proposed by several
authors [47,50,96,97]. It is suggested to be very promising
for a wide variety of patients, but due to the involvement
of NFκB in a wide variety of physiological processes, there
are safety implications. New drugs that target one of the
components of the NFκB pathway are currently under
development. One of these drugs, bortezomib, was
already launched in the United States in 2003 for the
treatment of multiple myeloma. Other drugs are in vari-
ous stages of development (table 3). The NFκB pathway
inhibitors are designed for the use in treatment of a variety
of disorders, including inflammatory diseases, autoim-
mune diseases, atopic disorders, arteriosclerosis and
malignancies. None of the drugs currently under develop-
ment is mentioned for treatment of CRPS. When these
drugs have proven to be safe, the therapeutic effect of
NFκB pathway inhibitors could be studied in CRPS
patients.
The entire CRPS pathogenesis. Starting point: hypoxic changesFigure 6
The entire CRPS pathogenesis. Starting point: hypoxic changes. Mediated by NFκB, a trigger that induces hypoxic 
changes can induce the entire pathogenesis of CRPS. SP = Substance P, CGRP = Calcitonin Gene-related Protein, VIP = 
Vasoactive Intestinal Protein, NPY = Neuropeptide Y, NPY-Y1-R = Neuropeptide Y-Y1 Receptor, NEP = Neutral-Endopepti-
dase, ACE = Angiotensin Converting Enzyme, SMP = Sympathetically Maintained Pain, NO = Nitric Oxide, iNOS = inducible 
Nitric Oxidase, ONOO = peroxynitrite
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Computer-assisted literature analysis to support the gen-
eration of novel and testable hypotheses has previously
been proven useful [5,6]. This study builds upon this
research, and extends it by bringing together researchers
and clinicians with a wide variety of backgrounds. An
experimental exercise was performed in which a text-min-
ing/entity relationship tool has been applied to systemat-
ically synthesize the knowledge in existing literature
about a complex disorder, exemplified by CRPS. Within
the created literature network, a simple knowledge gap
analysis was performed, using node connectivity. This
approach was essential in formulating the hypothesis that
NFκB might be a key player molecule in the pathogenesis
of CRPS. This example of multidisciplinary research illus-
trates how the collaborative efforts of investigators from
different fields of expertise can demonstrate new direc-
tions for future biological and epidemiological research
on a complex disease.
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